ArticleOpen access rheumatology : research and reviews2026
Vascular Involvement in Behçet's Disease: A Retrospective Analysis of Qatar Behçet's Cohort.
Article in Open access rheumatology : research and reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From inflammation to rupture: advances in the pathogenesis of pseudoaneurysm formation in Vascular Behçet's Disease.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Behçet's syndrome (BS) is a chronic systemic inflammatory disorder with vascular involvement representing a severe complication. Despite its high prevalence along the Silk Route, data on vascular Behçet's in Middle Eastern populations remain limited. Purpose: This study evaluates the prevalence, clinical features, and treatment outcomes of vascular BS in Qatar's multinational cohort. Patients and Methods: A retrospective analysis was conducted on 82 BS patients (2016-2024) meeting the International Criteria for Behçet's Disease (ICBD). Vascular involvement was confirmed via imaging (Doppler, CTA/MRA). Demographics, clinical manifestations, and treatment responses were characterized using descriptive analyses, and intervariable associations were statistically examined. Results: Vascular involvement was identified in 20.7% (17/82) of patients, with a male predominance (76.5%) and earlier diagnosis among Arab patients (29.3 vs. 44.3 years, p=0.02). Multivascular involvement was the most common pattern (35.3%), followed by isolated venous thrombosis (29.4%) and isolated arterial involvement (11.8%). Overall, venous disease was the predominant vascular manifestation, occurring either as isolated venous thrombosis or as part of combined arterial-venous involvement. The favorable clinical outcomes observed with corticosteroid-immunosuppressant combination therapy strongly support the early initiation of aggressive immunomodulatory treatment in patients with vascular Behçet's disease. Conclusion: In Qatar, about 1 in 5 patients with Behçet's disease show signs of vascular involvement, with notable differences based on ethnicity and gender. Venous and multivascular involvement are more common, making comprehensive imaging essential. Immunosuppression, particularly steroid-biologic combinations, appears superior to anticoagulation alone. These findings highlight the need for region-specific management protocols in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.